The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
INSIGHT: A phase 3, randomized, open-label study of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib with KIT exon 11 + 17/18 mutations.
 
John Raymond Zalcberg
Leadership - ICON Group; Lipotek; Praxis Therapeutics
Stock and Other Ownership Interests - Amarin Corporation; Biomarin; Concert Pharmaceuticals; Frequency Therapeutics; Gilead Sciences; Madrigal Pharmaceuticals; Moderna Therapeutics; Novavax; Opthea; Orphazyme; Teladoc; Twist Bioscience; UniQure; Zogenix
Honoraria - Gilead Sciences; MSD Oncology; Viatris
Consulting or Advisory Role - 1Globe Health Institute; Alloplex Biotherapeutics Inc; Center for Emerging & Neglected Diseases (CEND); Deciphera; FivePHusion; Genor BioPharma; Merck Sharp & Dohme; NOUS Group; Novotech; Oncology Republic; Revolution Medicines; Specialised Therapeutics
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Ipsen (Inst); IQvia (Inst); Medtronic (Inst); MSD Oncology (Inst); Mylan (Inst); Pfizer (Inst); Servier (Inst)
Travel, Accommodations, Expenses - ICON Group; MSD Oncology; Praxis Therapeutics
 
Jean-Yves Blay
Leadership - Innate Pharma
Honoraria - AstraZeneca; Bayer; BMS; Deciphera; Ignyta; MSD; PharmaMar; Roche
Consulting or Advisory Role - Bayer; Blueprint Medicines; Deciphera; Deciphera; Deciphera; Deciphera; Karyopharm Therapeutics; Pharmamar; Roche
Research Funding - AstraZeneca (Inst); Bayer (Inst); BMS (Inst); DEciphera (Inst); GlaxoSmithKline (Inst); MSD (Inst); Novartis (Inst); OSE Pharma (Inst); Pharmamar (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Roche
 
Ping Chi
Stock and Other Ownership Interests - ORIC Pharmaceuticals (I)
Consulting or Advisory Role - Deciphera; NewBay Pharma; Zai Lab
Research Funding - Deciphera (Inst); NewBay Pharma (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - ORIC Pharmaceuticals (I)
 
Robin Lewis Jones
Consulting or Advisory Role - Adaptimmune; Athenex; Bayer; Blueprint Medicines; Boehringer Ingelheim; Boehringer Ingelheim; Clinigen Group; Daiichi Sankyo; Deciphera; Eisai; Epizyme; Immodulon Therapeutics; Immune Design; Immunicum; Karma Oncology; Lilly; Merck Serono; Morphotek; Mundipharma; PharmaMar; SpringWorks Therapeutics; SynOX; TRACON Pharma; UpToDate
Research Funding - GlaxoSmithKline (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Cesar Serrano
Honoraria - Deciphera; PharmaMar; Roche
Consulting or Advisory Role - Blueprint Medicines; Cogent Biosciences; Deciphera; IDRX; Immunicum; NewBay Pharma
Research Funding - IDRX (Inst); Karyopharm Therapeutics (Inst)
Travel, Accommodations, Expenses - Bayer; Gilead Sciences; Pfizer; PharmaMar
 
Neeta Somaiah
Stock and Other Ownership Interests - JNJ (I); Pfizer (I)
Consulting or Advisory Role - AADi; Bayer; Blueprint Medicines; Boehringer Ingelheim; Deciphera; Epizyme
Research Funding - Advenc; Ascentage Pharma; AstraZeneca/MedImmune (Inst); Cogent Biosciences; Daiichi Sankyo/Lilly; Deciphera; GlaxoSmithKline; Karyopharm Therapeutics
 
William Reichmann
Employment - Deciphera
Stock and Other Ownership Interests - Deciphera
 
Kam Sprott
Employment - Deciphera; Stablix (I)
Stock and Other Ownership Interests - Deciphera; Stablix (I)
Consulting or Advisory Role - Ipsen (I)
 
Paulina Cox
No Relationships to Disclose
 
Matthew L. Sherman
Employment - Deciphera; Pieris Pharmaceuticals
Leadership - Deciphera; Pieris Pharmaceuticals
Stock and Other Ownership Interests - Deciphera; Pieris Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Acceleron Pharma
 
Rodrigo Ruiz-Soto
Employment - Deciphera
Stock and Other Ownership Interests - Deciphera; Immunogen
Patents, Royalties, Other Intellectual Property - I am an inventor in 3 patents with Immunogen, I transferred the rights to Immunogen. I have not received (and I will not receive) any royalties; I am an inventor in pending patents at Deciphera. I have transferred the rights to Deciphera, I have not received (and will not receive) any royalties
 
Michael C. Heinrich
Honoraria - Novartis
Consulting or Advisory Role - Cogent Pharmaceuticals; Deciphera; Novartis; Theseus Pharmaceuticals
Research Funding - Cogent Biosciences
Patents, Royalties, Other Intellectual Property - Patent on treatment of GIST-licensed to Novartis (Inst)
 
Sebastian Bauer
Honoraria - Deciphera; GlaxoSmithKline; Novartis; Pharmamar
Consulting or Advisory Role - ADC Therapeutics; Adcendo; Bayer; Blueprint Medicines; Boehringer Ingelheim; Daiichi Sankyo; Deciphera; Exelixis; GlaxoSmithKline; IDRX; Janssen-Cilag; Lilly; Mundipharma; Nanobiotix
Research Funding - Blueprint Medicines; Incyte (Inst); Novartis
Travel, Accommodations, Expenses - Pharmamar
 
Suzanne George
Stock and Other Ownership Interests - Abbott Laboratories
Honoraria - CStone Pharmaceuticals
Consulting or Advisory Role - Bayer; BioAtla; Blueprint Medicines; Daiichi; deciphera; Immunicum; Kayothera; Lilly; MORE Health; Research to Practice; UpToDate
Research Funding - Acrivon Therapeutics; BioAtla; Blueprint Medicines (Inst); Daiichi Sankyo RD Novare (Inst); Deciphera (Inst); Eisai (Inst); IDRx (Inst); Merck (Inst); NewBay Pharma (Inst); SpringWorks Therapeutics (Inst); Theseus Pharmaceuticals (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - UptoDate
Expert Testimony - Bayer
Other Relationship - Research to Practice; WCG